NEW YORK, Sept. 18-Perlegen will work with GlaxoSmithKline in a whole genome scanning project to identify drug response markers, the company said today.
The collaboration is based upon Perlegen's technique for using high-density microarrays for sequencing, SNP discovery, and haplotype identification. It will "complement" GSK's in-house research, a company representative said in a statement.
Using this technique, Perlegen says it can sequence an entire genome in ten days.
The companies did not disclose the financial details of this collaboration.